Best of ASCO - 2014 Annual Meeting

 

Welcome

Immune Checkpoint Inhibitors

Developmental Therapeutics—Immunotherapy

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
In silico approach to inhibit the checkpoint protein PD-1by the monoclonal antibody nivolumab.

E.L. Albuquerque

e15089

A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.

Jian-Ming Xu

e15125

A glyco-immune checkpoint: Modulation of the immune micro-environment and induction of stem cell-like properties in breast cancer cells.

Joy M Burchell

e15104

A longitudinal retrospective case series of the real-world toxicities encountered among cancer patients receiving anti-PD-L1 checkpoint inhibitor immunotherapy.

Anastasios L. Boutis

e15117

A meta-analysis to indirectly compare the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors using a Bayesian hierarchical model.

Mythili Koneru

3065

A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).

Xabier Mielgo

TPS3123

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

Nehal J. Lakhani

3068

A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.

Fortunato Ciardiello

TPS3114

A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.

Dingzhi Huang

TPS3112

A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Lin Shen

TPS3111

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Shukui Qin

TPS3110

A phase I study of JS001, a humanized PD-1mAbin patients with advanced triple negative breast cancer.

Li Bian

e15093

A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors.

Jianming Xu

e15138

A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors.

Sophie Cousin

TPS3125

A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies.

Jia Wei

TPS3118

A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.

Chrystal Ann Landry

TPS3116

A review of the patterns of prescribing, efficacy and toxicities for patients receiving checkpoint inhibitors.

Peter Nightingale

e15090

A single-institution study of renal outcomes in patients receiving checkpoint inhibitors.

Sarah Mushtaq

e15079

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.

Mallika Lala

3062

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.

Kyriakos P. Papadopoulos

TPS3127

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

Roy S. Herbst

3059

Adoption rates of immune checkpoint inhibitors in real world oncology practice.

Jennifer O. Nwankwo

e15103

Allo-immunity and graft rejection after checkpoint inhibitor therapy (CPI) in solid organ transplant (SOT) recipients.

Noha Abdel-Wahab

3082

An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.

Takashi Kojima

TPS3117

An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).

John Heymach

TPS3120

An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).

Karim Fizazi

TPS3126

Analysis of patient related and trial related factors leading to non-participation of patients with advanced cancer in immunotherapy clinical trials: Implications for modifying eligibility criteria.

Ishwaria Mohan Subbiah

e15066

Antibiotic use and overall survival in lung cancer patients receiving nivolumab.

Tien Phuc Do

e15109

Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.

Rachel E. Sanborn

3001

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.

Laia Pare

3076

Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.

Karen Kelly

3057

Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.

Shota Fukuoka

3011

Association of immune related adverse events with improved progression-free survival in patients receiving anti-PD-1 / PD-L1 therapy irrespective of corticosteroid use.

Hammad Shafqat

e15088

Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.

Vylyny Chat

3079

Can body composition (BC) be predictive for outcomes and severe toxicities (ST) in metastatic solid tumors patients (pts) treated with checkpoint inhibitor (CPI)? An analysis of 145 patients.

Sophie Cousin

3069

Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.

Laleh Amiri-Kordestani

3009

Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).

Justine Vanessa Cohen

3087

Checkpoint inhibitor induced glomerulonephritis.

Ala Abudayyeh

e15083

Circulating miRNA and extracellular vesicle containing miRNA as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.

Takehito Shukuya

3058

Clinical and pharmacological parameters associated with nivolumab toxicity.

Laure Hirsch

3066

Clinical parameters predicting response and outcomes to immunotherapy in metastatic cancers.

Rohan Garje

e15084

Combating of non-small-cell lung cancer (NSCLC) through EGFR/PD-L1 bispecific antibody generated by Lock-and-Key method.

Lei Zhao

e15106

Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials.

Elvire Pons-Tostivint

3070

Concurrent nivolumab and radiotherapy to improve outcomes for patients with metastatic lung and renal cancers.

Jawaher Ansari

e15078

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

Mariona Riudavets

3064

Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro).

Lawrence H. Schwartz

3017

Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.

Jacqueline N. Chu

3060

Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

Jacqueline N. Chu

e15134

Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer.

Nadina Tinsley

3010

Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).

Neil J. Shah

e15074

Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX).

Fabian Dominik Mairinger

e15121

Do immune-related adverse effects predict better outcomes in lung cancer?

Prashant Mukesh Jani

e15067

Dynamic testing of positive and negative biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.

Wushuang Du

e15131

Effect of pretreatment steroids on the development of immune related adverse events.

Philip Margiotta

e15095

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.

Luca Rastelli

3085

Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients.

Shahla Bari

e15080

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Fernando Manuel Vargas Madueno

TPS3108

Evaluating the utility of pretreatment C-reactive protein (CRP) in survival stratification of advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint blockade (ICB): A prospective cohort study.

Abdul Rafeh Naqash

e15122

Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.

Niels Halama

e15094

Expansion cohort of partially irradiated tumors on a phase 1 trial of pembrolizumab and ablative radiotherapy.

Sandeep Ramesh BHave

TPS3122

Generation of anti-human TIM-3 monoclonal antibody for cancer immunotherapy.

Yu-Chen Yang

e15135

Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.

Yada Kanjanapan

3063

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

Timothy Anthony Yap

3000

Immunotherapy efficacy and toxicity in a real-world elderly population.

Joobin Sattar

e15137

Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.

Kushal Gupta

e15065

Impact of age on immune checkpoint blockade tolerability across malignancies: A single institution review.

Sharon Li

e15069

Impact of comorbidity on immune checkpoint blockade tolerance across tumor types.

Sean Clark-Garvey

e15068

Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.

Shiraj Sen

3077

Intestinal microbiota to predict lung cancer patients at risk of immune-related diarrhea.

Tian Liu

3067

Long-term outcomes in patients after discontinuation of PD1/PDL1 inhibitors.

Zin Myint

e15086

Mapping PD-1 inhibitors’ side effects using patient-reported outcomes (PRO) generated by a digital patient-powered network (PPN).

Daniel A. Vorobiof

e15087

Monitoring of thyroid function test abnormalities in cancer patients undergoing immune checkpoint inhibitor therapy in a community based cancer center.

Mehmet Sitki Copur

e15064

Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.

Dan Moldoveanu

e15071

Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.

Bianca Santomasso

3084

Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Diana Saravia

e15102

Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.

Ian Chau

e15127

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

Adi Diab

3006

Novel anti-PD-1 antibodies not acting through PD-1/pdl-1 blockade that enhance tumor clearance.

Craig Fenwick

e15118

PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC).

David Jacob Hermel

e15100

Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Jianliang Yang

e15108

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

Kathleen N. Moore

3086

Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

Jayesh Desai

TPS3113

Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.

Dejan Juric

e15124

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

Ignacio Melero Bermejo

TPS3109

Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.

Breelyn A. Wilky

3075

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

David S. Hong

3012

Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.

Toshio Kubo

TPS3119

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

Aitana Calvo

3014

Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.

James Lorens

3078

Pre-clinical assessment of rational design immuno-oncology biologics with improved therapeutic indices.

Margaret Karow

e15096

Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.

Wungki Park

3015

Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.

Rachel E. Sanborn

3072

Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.

Karen A. Autio

3071

Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.

Hashim Mann

e15092

Prevalence of microsatellite instability and association with pembrolizumab (P) usage in a real-world clinico-genomic database.

Claire O'Connell

e15072

PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.

Daniel A. Vaena

TPS3115

Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

Melissa A. Eastgate

e15099

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.

David Cella

3073

Radiologic predictors of response to checkpoint inhibitors in advanced head and neck SCC.

Vishwajith Sridharan

e15133

Real-world data analysis of immune checkpoint inhibitor utilization by tumor type in the US community oncology setting.

Jeffrey A. Scott

e15076

Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603).

Shota Fukuoka

TPS3124

Remodeling tumor-associated macrophages with a CD47xMesothelin bispecific antibody for efficient elimination of solid tumor cells.

Walter G. Ferlin

e15126

Repurposing tin mesoporphyrin as a novel immune checkpoint therapy in the treatment of cancer: A preclinical evaluation.

James N. Arnold

e15129

Retrospective review of immune checkpoint inhibitor therapy (ICI) at the Michael E. DeBakey VA Medical Center Cancer Center (MEDVAMCCC).

Jan Ole Kemnade

e15091

Risk factors for pneumonitis in solid tumors treated with anti-programmed death-1 therapy: A case-control study.

Pengfei Cui

e15132

Role of melanoma cell-intrinsic RIG-I and STING signaling for checkpoint inhibitor-mediated anticancer immunity.

Simon Heidegger

3081

Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.

Julius Strauss

3007

Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).

Andreea Varga

3080

Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer.

Curtis Robert Chong

e15073

Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.

Benjamin Izar

3074

Testicular histopathology after immunotherapy for metastatic melanoma.

Karl S Benz

e15114

The impact of patient age on toxicity and efficacy of immunotherapy agents.

Shuai Zhang

e15116

Therapy selection and monitoring of early and late stage non small cell lung cancer (NSCLC) using a novel circulating tumor cells (CTCs) PD-L1 blood test.

Yen-Lin Chen

e15107

Treating the elderly with immune checkpoint inhibitors: Real life experience from a large Brazilian center.

Clarissa Cavalin Silva

e15077

Trial in progress: Platform phase 1 study investigating the safety of stereotactic body radiotherapy with immuno-oncology agents for the treatment of multiple metastases in advanced solid tumors.

Corey Christian Foster

TPS3121

Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Sacha Rothschild

e15075

Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.

Jeffrey Melson Clarke

3061